2024
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy
Ma J, Dong C, Qiao H, Barret O, Tamagnan G, Mao W, Xu E, Zhang C, Lu J, Chan P, Liu S. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy. Movement Disorders 2024, 39: 847-854. PMID: 38477228, DOI: 10.1002/mds.29769.Peer-Reviewed Original ResearchVesicular monoamine transporter 2Vesicular monoamine transporter 2 bindingProgressive supranuclear palsy groupPositron emission tomographyProgressive supranuclear palsyHealthy controlsParkinson's diseaseStriatal VMAT2 bindingMonoamine transporter 2Mini-Mental State ExaminationNucleus accumbensMontreal Cognitive AssessmentVMAT2 bindingRating ScaleCognitive AssessmentSubstantia nigraMini-MentalSupranuclear palsyState ExaminationProgressive Supranuclear Palsy Rating ScaleHippocampusPET/computed tomographyPD groupClinical characteristicsStriatum
2023
18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease
Huang A, Liu S, Barret O, Qiao H, Tamagnan G, Liu X, Fan C, Li Z, Lu J, Chan P, Xu E. 18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease. Parkinsonism & Related Disorders 2023, 120: 105979. PMID: 38241952, DOI: 10.1016/j.parkreldis.2023.105979.Peer-Reviewed Original ResearchPostural instability gait difficultyMotor subtypesParkinson's diseaseStandardized uptake value ratioDifferent motor subtypesStriatal dopaminergic depletionParkinsonian motor symptomsUptake value ratioPET/CTDopaminergic disruptionMonoaminergic depletionMonoaminergic changesDopaminergic depletionMotor symptomsPIGD scoresDorsal putamenPD subtypesVentral putamenPD pathogenesisPrognosis evaluationPatientsDominant subtypeMethods SixtyAccurate diagnosisDifferent subtypes
2015
Imaging Studies with A2A Receptor Antagonists
Tavares A, Barret O, Seibyl J, Tamagnan G. Imaging Studies with A2A Receptor Antagonists. Current Topics In Neurotoxicity 2015, 10: 207-232. DOI: 10.1007/978-3-319-20273-0_11.Peer-Reviewed Original ResearchPositron emission tomographyValue of PETA2A receptor antagonistsSingle photon emissionPathophysiological progressionReceptor antagonistClinical studiesDifferential diagnosisParkinson's diseaseIodine-123Imaging studiesEmission tomographyNeuropsychiatric disordersSPECT probeSPECT techniqueSPECT radiotracerPET imagingA2AVivo characteristicsBrainSPECTPhoton emissionVivo propertiesRadiotracerRecent reportsSynthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB)
Liang S, Yokell D, Jackson R, Rice P, Livni E, Alagille D, Tamagnan G, Collier T, Vasdev N. Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB). 2015, 41-51. DOI: 10.1002/9781118834114.ch5.Peer-Reviewed Original ResearchMetabotropic glutamate receptor subtype 5Regional brain concentrationsHealthy human subjectsBrain concentrationsBrain penetranceMGluR5 antagonistSubtype 5Parkinson's diseasePathologic processesAlzheimer's diseaseNeuropsychiatric disordersNeurodegenerative diseasesDiseaseHigh potencyHuman subjectsEvidence pointsFragile X syndromeControl testsRadiochemical purityCritical roleX syndromeMGluR5SyndromeAntagonistAbnormalities